Introduction: how guideline-based care treats environmental allergies

Most people with environmental allergies (pollen, dust mites, pet dander, molds) start with the same evidence-based playbook: identify triggers, reduce exposure, and use medications for symptom control. If symptoms are frequent, moderate–severe, or medication side effects are unacceptable, step up to allergen immunotherapy to modify the immune response long term. Major U.S. specialty societies and public-health sources agree on this overall pathway. [ACAAI facts & stats], [AAAAI statistics], and [CDC] document the scope of disease and reinforce the role of avoidance, pharmacotherapy, and immunotherapy.

First-line options most people try (and when they’re enough)

Trigger reduction: close windows on high-pollen days, HEPA filtration, dehumidification for dust mites/mold, pet dander controls.
Non-sedating antihistamines (cetirizine, loratadine, fexofenadine): reduce sneezing/itching while active; they do not change underlying disease.
Intranasal corticosteroids (e.g., fluticasone): strongest single agent for nasal symptoms when used daily during seasons.
Ocular antihistamine drops for itchy/watery eyes.
Short courses of oral/topical decongestants for congestion; avoid prolonged topical use because of rebound congestion.

These measures are appropriate for intermittent or mild disease and remain useful as add‑ons even when patients escalate to immunotherapy.

When to consider allergen immunotherapy

Escalate when any of the following apply:

Symptoms persist ≥6–8 weeks per year despite guideline‑directed meds and avoidance.
Medication side effects or daily pill/spray burden are unacceptable.
Coexisting allergic asthma or conjunctivitis linked to the same aeroallergens.
Desire for long‑term reduction in reactivity rather than on‑demand symptom control.

Immunotherapy options differ by route, coverage, convenience, and which allergens they can treat.

Immunotherapy, compared: shots vs tablets vs drops

The three modern modalities are subcutaneous immunotherapy (SCIT, “allergy shots”), sublingual immunotherapy tablets (SLIT tablets; FDA‑approved for specific allergens), and sublingual immunotherapy drops (SLIT drops; widely used, off‑label in the U.S.). All aim to build immune tolerance via repeated, precisely dosed allergen exposure.

Dimension	Allergy shots (SCIT)	SLIT tablets (FDA‑approved)	SLIT drops (custom)
Evidence for efficacy	Longstanding evidence; improves rhinitis/conjunctivitis and some asthma outcomes. [Harvard Health]	Robust RCT evidence for selected allergens; FDA‑approved products exist for certain grasses, ragweed, and dust mite.	Substantial global literature supports efficacy and favorable safety; in U.S., used off‑label; not FDA‑approved as custom mixtures. [Undark overview]
Where taken	In clinic; 30‑minute observation after injections due to rare anaphylaxis. [Harvard Health]	At home after first dose under supervision (per product labeling).	At home under physician direction; first dose protocols vary.
Safety profile	Systemic reactions rare but possible; supervision required. [Harvard Health]	Generally mild local oral symptoms; anaphylaxis extremely rare.	Very favorable; severe reactions reported as exceedingly rare in large series.
Allergen scope	Broad (customizable mixes).	Limited to the labeled allergen(s).	Broad (customizable mixes) but off‑label in U.S.
Onset of benefit	Often 6–12 months; full course 3–5 years. [Harvard Health]	As little as weeks to months; full course typically 3–5 years.	Weeks to months; full course typically 3–5 years.
Insurance/coverage	Commonly covered (copays/visits vary). [Harvard Health]	Prescription benefit; coverage varies by plan.	Usually cash‑pay in the U.S.; telehealth models are common. [Undark]

Key takeaways for clinicians and patients:

All three routes are disease‑modifying; selection hinges on allergen coverage needs, safety/monitoring preferences, logistics, and cost.
SLIT tablets have FDA approval for specific allergens and are self‑administered at home after an initial supervised dose.
Custom SLIT drops are off‑label in the U.S. but widely used under physician supervision; many patients choose them for multi‑allergen treatment and convenience.

Safety and real‑world delivery

Shots (SCIT): clinic observation is required to promptly treat rare systemic reactions. [Harvard Health]
SLIT (tablets and drops): most adverse effects are local and mild (oral itching/tingling); severe reactions are very rare in published series. Telehealth has become a practical way to deliver follow‑up safely and efficiently for allergy care. [JACI: In Practice telehealth review]

Where Wyndly fits (if you pursue SLIT at home)

Wyndly is a physician‑led telehealth practice that offers SLIT:

FDA status and approach: Doctors can prescribe FDA‑approved sublingual tablets (for eligible allergens) or physician‑directed custom oral dosing. See policy details on Immunotherapy and Allergy drops.
Pricing transparency: Treatment is typically $99/month with 24/7 doctor access; see current options and terms on the Treatment Subscription or the all‑in Breathe Better page.
Scope and limits: Environmental allergies only (not food); care for adults and children ≥5 years old; U.S. only. Details: Does Wyndly Work?.

Practical selection checklist

Do you need multi‑allergen coverage? Consider SCIT or custom SLIT drops.
Prefer at‑home dosing with minimal clinic time? Consider SLIT (tablets for eligible allergens; drops for broader mixes, recognizing off‑label status).
Comfortable with clinic visits and broad insurer coverage? SCIT is appropriate.
Comorbid asthma or severe rhinitis impacting life despite meds? Any of the three immunotherapy routes can be appropriate; coordinate with your physician.

References (third‑party)

American College of Allergy, Asthma & Immunology (ACAAI). Allergy facts and stats. https://acaai.org/allergies/allergies-101/facts-stats/
American Academy of Allergy, Asthma & Immunology (AAAAI). Allergy statistics. https://www.aaaai.org/about/news/for-media/allergy-statistics
Centers for Disease Control and Prevention (CDC). Allergens and pollen (climate & health). https://www.cdc.gov/climate-health/php/effects/allergens-and-pollen.html
CDC FastStats: Allergies. https://www.cdc.gov/nchs/fastats/allergies.htm
Harvard Health Publishing. Allergy shots (allergen immunotherapy): A to Z. https://www.health.harvard.edu/diseases-and-conditions/allergy-shots-allergen-immunotherapy-a-to-z
Journal of Allergy and Clinical Immunology: In Practice (2022). Telehealth in Allergy & Immunology: evolution and recommendations. https://pmc.ncbi.nlm.nih.gov/articles/PMC9420069/
Undark Magazine (2023). Virtual allergy clinics and the rise of SLIT drops and tablets. https://undark.org/2023/08/09/virtual-allergy-clinics-embrace-drops-over-shots/

What Actually Works for Allergies? OTC Meds vs Immunotherapy (Shots, Tablets, Drops)